Shanghai Fenghua Tianlitong Biomedical

Shanghai Fenghua Tianlitong Biomedical is a Chinese biotechnology company focused on the development of advanced thrombolytic therapies for cardiovascular and cerebrovascular diseases. Established in 2020 as a subsidiary of Fenghua Bio, the company operates an R&D center in the Zhangjiang Cell Industrial Park in Shanghai. Its lead candidate, Tianlitong (a tenecteplase biosimilar), is currently in Phase 3 clinical trials for the treatment of acute ischemic stroke and Phase 2 for acute pulmonary embolism. The company leverages genetic recombination and monoclonal antibody technologies to develop third-generation thrombolytic agents with improved efficacy and safety profiles compared to traditional tissue plasminogen activators.